Yazar "Eroglu, M." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    AN UNUSUAL COMPLICATION OF URETERAL DOUBLE-J STENT PLACEMENT: URETERAL PERFORATION
    (Assoc Royal Soc Scientifiques Medicales Belges, 2014) Resorlu, M.; Karakan, T.; Kabar, M.; Demirbas, A.; Demir, D. Orsan; Eroglu, M.
    [Anstract Not Available]
  • [ X ]
    Öğe
    Are Small Adrenal Incidentalomas Solely a Radiological Finding?
    (Johann Ambrosius Barth Verlag Medizinverlage Heidelberg Gmbh, 2015) Eroglu, M.; Erbag, G.; Turkon, H.; Binnetoglu, E.; Ozkul, F.; Gunes, F.; Sen, H.
    Objective: The criterium defining the threshold size of adrenal incidentaloma (AI) is a size greater than 1cm diameter. However, data concerning AI1cm in diameter is scant. The aim of this study was to evaluate the function of adrenal masses1cm and to compare them with adrenal masses>1cm. Materials and Methods: The study included 130 consecutive patients with AI (38 and 92 AI at 1cm and >1cm, respectively). The patients were evaluated according to demographic and hormonal characteristics. Results: The prevalence of SCS was 5.3 and 12% in AI1cm and >1cm diameter, respectively. Hyperaldosteronism was found only in patients with >1cm AI. Pheochromocytoma were not found in either group. Patients with >1cm AI had a higher prevalence of SCS and primary hyperaldosteronism than patients with 1cm AI, but the difference was not significant. The prevalence of diabetes and hypertension was high both in non-functional AI with 1cm and >1cm patients and showed no significant difference between the 2 groups. Conclusion: Our study is the first to focus on the clinical and hormonal characteristics of patients with 1cm AI. Those with AI1cm harboured SCS, as was the case for AI>1cm. Similar to AI>1cm, non-functional AI1cm also had a higher prevalence of diabetes and hypertension.
  • [ X ]
    Öğe
    Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome
    (C M B Assoc, 2016) Erbag, G.; Eroglu, M.; Turkon, H.; Sen, H.; Binnetoglu, E.; Aylanc, N.; Asik, M.
    To evaluate the status of serum betatrophin levels and potential relations between metabolic parameters and betatrophin levels in patients with polycystic ovary syndrome. We included patients newly diagnosed with PCOS in our study. Fifty-seven female patients (30 patients with PCOS and 27 healthy control subjects) were enrolled in this study. Serum betatrophin levels were measured using a betatrophin enzyme-linked immunosorbent assay kit. Insulin resistance was calculated using the homeostasis model of the assessment-insulin resistance index formula. The betatrophin level was 1538,85 ng/L in the patient group and 2440,46 ng/L in the control group, and the difference was statistically significant (p=0.003). A significantly negative correlation was found between betatrophin level and insulin, HOMA-IR, and BMI. Betatrophin levels in patients with PCOS are lower than those without PCOS and inversely related to insulin resistance.